Prime Medicine

PRMENasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$556.302 M

$3.08 +4.41%

Close of 7 Aug 2026

Revenue

$4.63M

#3317 by revenue

Earnings

-$201.1M

Loss-making

Shares outstanding

181,376,856

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#624D Molecular TherapeuticsFDMT$562.0M
#63Autolus TherapeuticsAUTL$561.6M
#64Prime MedicinePRME$556.3M
#65RegenxbioRGNX$554.2M
#66Artiva BiotherapeuticsARTV$550.9M

Where these numbers come from

Share counts and financials for Prime Medicine are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.